Review article: bone disease in inflammatory bowel disease

Area of Science:

• Gastroenterology and Endocrinology
• Bone Metabolism and Disease

Background:

• Inflammatory bowel disease (IBD) significantly increases osteoporosis risk, leading to pain, fractures, and reduced quality of life.
• Current strategies for identifying at-risk patients and effective prevention remain underdeveloped.

Purpose of the Study:

• To review the prevalence, risk factors, and management strategies for osteoporosis associated with inflammatory bowel disease.

Main Methods:

• Literature review focusing on epidemiological data, risk factors (age, weight, corticosteroid use), and current treatment guidelines for IBD-associated osteoporosis.
• Analysis of treatment options including lifestyle modifications, nutritional supplements, hormone replacement therapy, bisphosphonates, and emerging therapies.

Main Results:

• Osteoporosis affects 15% of IBD patients, with fracture incidence at 1 per 100 patient-years, escalating with age.
• Corticosteroid use is a key factor in bone loss, though distinguishing its effect from disease activity is challenging.
• Treatment recommendations align with postmenopausal osteoporosis, emphasizing lifestyle, vitamin D, calcium, and pharmacotherapy.

Conclusions:

• Increased awareness of IBD-associated osteoporosis is crucial.
• Further research is needed to refine patient identification and establish evidence-based prevention strategies.
• Emerging treatments show promise for both steroid-induced and inflammation-mediated bone loss in IBD.